Control of the Lung Residence Time of Highly Permeable Molecules After Nebulization: Example of the Fluoroquinolones

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Apr 29

PMID 32340298

Citations 10

Authors

Julien Brillault

Frederic Tewes

Affiliations

Soon will be listed here.

Abstract

Pulmonary drug delivery is a promising strategy to treat lung infectious disease as it allows for a high local drug concentration and low systemic side effects. This is particularly true for low-permeability drugs, such as tobramycin or colistin, that penetrate the lung at a low rate after systemic administration and greatly benefit from lung administration in terms of the local drug concentration. However, for relatively high-permeable drugs, such as fluoroquinolones (FQs), the rate of absorption is so high that the pulmonary administration has no therapeutic advantage compared to systemic or oral administration. Formulation strategies have thus been developed to decrease the absorption rate and increase FQs' residence time in the lung after inhalation. In the present review, some of these strategies, which generally consist of either decreasing the lung epithelium permeability or decreasing the release rate of FQs into the epithelial lining fluid after lung deposition, are presented in regards to their clinical aspects.

Citing Articles

Biopharmaceutical profiling of anti-infective sanggenons from root bark for inhalation administration.

Schwarzinger J, Adelsberger S, Ortmayr K, Stellnberger S, Tahir A, Hadrich G Int J Pharm X. 2024; 8:100272.

PMID: 39252692 PMC: 11381475. DOI: 10.1016/j.ijpx.2024.100272.

Evaluating the effect of sodium alginate and sodium carboxymethylcellulose on pulmonary delivery of levofloxacin spray-dried microparticles.

Alizadeh H, Khoshhal P, Mirmoeini M, Gilani K Daru. 2024; 32(2):557-571.

PMID: 38955893 PMC: 11554959. DOI: 10.1007/s40199-024-00526-x.

The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel.

Alsmadi M, Jaradat M, Obaidat R, Alnaief M, Tayyem R, Idkaidek N AAPS PharmSciTech. 2023; 24(6):172.

PMID: 37566183 DOI: 10.1208/s12249-023-02627-3.

PK-PD Evaluation of Inhaled Microparticles loaded with Ciprofloxacin-Copper complex in a Rat Model of Chronic Lung Infection.

Tewes F, Lamy B, Laroche J, Lamarche I, Marchand S Int J Pharm X. 2023; 5:100178.

PMID: 36970713 PMC: 10033950. DOI: 10.1016/j.ijpx.2023.100178.

Ruthenium(II) Polypyridyl Complexes for Antimicrobial Photodynamic Therapy: Prospects for Application in Cystic Fibrosis Lung Airways.

Youf R, Nasir A, Muller M, Thetiot F, Haute T, Ghanem R Pharmaceutics. 2022; 14(8).

PMID: 36015290 PMC: 9412327. DOI: 10.3390/pharmaceutics14081664.

References

Sibum I, Hagedoorn P, de Boer A, Frijlink H, Grasmeijer F . Challenges for pulmonary delivery of high powder doses. Int J Pharm. 2018; 548(1):325-336. DOI: 10.1016/j.ijpharm.2018.07.008. View

Wehbe M, Leung A, Abrams M, Orvig C, Bally M . A Perspective - can copper complexes be developed as a novel class of therapeutics?. Dalton Trans. 2017; 46(33):10758-10773. DOI: 10.1039/c7dt01955f. View

Weers J, Tarara T . The PulmoSphere™ platform for pulmonary drug delivery. Ther Deliv. 2014; 5(3):277-95. DOI: 10.4155/tde.14.3. View

Blokhina S, Sharapova A, Olkhovich M, Volkova T, Perlovich G . Solubility, lipophilicity and membrane permeability of some fluoroquinolone antimicrobials. Eur J Pharm Sci. 2016; 93:29-37. DOI: 10.1016/j.ejps.2016.07.016. View

Gontijo A, Gregoire N, Lamarche I, Gobin P, Couet W, Marchand S . Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin. Antimicrob Agents Chemother. 2014; 58(7):3950-6. PMC: 4068596. DOI: 10.1128/AAC.02819-14. View

Wilson R, Welte T, Polverino E, Soyza A, Greville H, ODonnell A . Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2012; 41(5):1107-15. PMC: 3640146. DOI: 10.1183/09031936.00071312. View

Bragonzi A, Worlitzsch D, Pier G, Timpert P, Ulrich M, Hentzer M . Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model. J Infect Dis. 2005; 192(3):410-9. PMC: 1317300. DOI: 10.1086/431516. View

Torres B, Awad R, Marchand S, Couet W, Tewes F . In vitro evaluation of Pseudomonas aeruginosa chronic lung infection models: Are agar and calcium-alginate beads interchangeable?. Eur J Pharm Biopharm. 2019; 143:35-43. DOI: 10.1016/j.ejpb.2019.08.006. View

Seedher N, Agarwal P . Effect of metal ions on some pharmacologically relevant interactions involving fluoroquinolone antibiotics. Drug Metabol Drug Interact. 2011; 25(1-4):17-24. DOI: 10.1515/DMDI.2010.003. View

10.

Wallis S, Charles B, Gahan L, Filippich L, Bredhauer M, Duckworth P . Interaction of norfloxacin with divalent and trivalent pharmaceutical cations. In vitro complexation and in vivo pharmacokinetic studies in the dog. J Pharm Sci. 1996; 85(8):803-9. DOI: 10.1021/js960087f. View

11.

Forde E, Devocelle M . Pro-moieties of antimicrobial peptide prodrugs. Molecules. 2015; 20(1):1210-27. PMC: 6272668. DOI: 10.3390/molecules20011210. View

12.

Muller L, Murgia X, Siebenburger L, Borger C, Schwarzkopf K, Sewald K . Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin. J Antimicrob Chemother. 2018; 73(10):2762-2769. DOI: 10.1093/jac/dky241. View

13.

Nurbaeti S, Brillault J, Tewes F, Olivier J . Sustained-release microparticle dry powders of chloramphenicol palmitate or thiamphenicol palmitate prodrugs for lung delivery as aerosols. Eur J Pharm Sci. 2019; 138:105028. DOI: 10.1016/j.ejps.2019.105028. View

14.

Tewes F, Gobbo O, Ehrhardt C, Healy A . Amorphous Calcium Carbonate Based-Microparticles for Peptide Pulmonary Delivery. ACS Appl Mater Interfaces. 2015; 8(2):1164-75. DOI: 10.1021/acsami.5b09023. View

15.

Cipolla D, Shekunov B, Blanchard J, Hickey A . Lipid-based carriers for pulmonary products: preclinical development and case studies in humans. Adv Drug Deliv Rev. 2014; 75:53-80. DOI: 10.1016/j.addr.2014.05.001. View

16.

Mutti A, Corradi M, Goldoni M, Vettori M, Bernard A, Apostoli P . Exhaled metallic elements and serum pneumoproteins in asymptomatic smokers and patients with COPD or asthma. Chest. 2006; 129(5):1288-97. PMC: 1472634. DOI: 10.1378/chest.129.5.1288. View

17.

Gunday Tureli N, Torge A, Juntke J, Schwarz B, Schneider-Daum N, Tureli A . Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections. Eur J Pharm Biopharm. 2017; 117:363-371. DOI: 10.1016/j.ejpb.2017.04.032. View

18.

King P, Lomovskaya O, Griffith D, Burns J, Dudley M . In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother. 2009; 54(1):143-8. PMC: 2798504. DOI: 10.1128/AAC.00248-09. View

19.

Cao B, Christophersen L, Kolpen M, Jensen P, Sneppen K, Hoiby N . Diffusion Retardation by Binding of Tobramycin in an Alginate Biofilm Model. PLoS One. 2016; 11(4):e0153616. PMC: 4839563. DOI: 10.1371/journal.pone.0153616. View

20.

Ovet H, Oztay F . The copper chelator tetrathiomolybdate regressed bleomycin-induced pulmonary fibrosis in mice, by reducing lysyl oxidase expressions. Biol Trace Elem Res. 2014; 162(1-3):189-99. DOI: 10.1007/s12011-014-0142-1. View